lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Phenelzine, sold under the brand name Nardil among others, is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine family which is primarily used as an antidepressant and anxiolytic to treat depression and anxiety. Along with tranylcypromine and isocarboxazid, phenelzine is one of the few non-selective and irreversible MAOIs still in widespread clinical use.
Dayhoff was born an only child in Philadelphia, but moved to New York City when she was ten. Her academic promise was evident from the outset – she was valedictorian (class of 1942) at Bayside High School, Bayside, New York, and from there received a scholarship to Washington Square College of New York University, graduating magna cum laude in mathematics in 1945 and getting elected to Phi Beta Kappa.
Some authors use the quantity S/f as the sorptivity. The above description is for the case where gravity and evaporation do not play a role. Sorptivity is a relevant property of building materials, because it affects the amount of rising dampness. Some values for the sorptivity of building materials are in the table below.
== Publications == English Seafood Cookery, 1988 – Glenfiddich Cook Book of the Year 1989 A Beginner's Guide to Seafood, 1992 (Chapter 4 Marine Cuisine Guides) Beach to Belly, 1994 (foreword) Taste of the Sea, 1995 – André Simon Cook Book of the Year 1996 Good Food Award Best Cookery Book, 1995/1996 Rick Stein Fish, 10 Recipes, 1996 Fruits of the Sea (ISBN 0-563-38457-3), 1997 Rick Stein's Seafood Odyssey (ISBN 978-0-563-38440-3), 1999 Rick Stein's Seafood Lovers' Guide (ISBN 0-563-48871-9), 2000 Rick Stein's Seafood, 2001 - Gourmand World Cookbook Awards, 2001 – winner of category: Best Seafood and Fish in English; Best in the World Fish and Seafood (German translation – Gold medal – Gastronomische Akademie Deutschland 2003) My Favourite Seafood Recipes, 2002 (Marks and Spencer cookery book) Rick Stein's Food Heroes, 2002 – Gourmand World Cookbook Awards 2002 – winner of category: Best Local Cookery Book; Best Cookery Book of the Year in Great Britain / Jacob's Creek World Food Media Awards 2003: Silver for best hardcover recipe book Rick Stein's Guide to the Food Heroes of Britain (ISBN 0-563-52175-9), 2003 – Gourmand World Cookbook Awards 2003 – winner of category: Best Guide Rick Stein's Food Heroes, Another Helping (ISBN 0-56348-752-6), 2004 Rick Stein's Complete Seafood (ISBN 1-58008-568-7) – winner of the James Beard Foundation Award 2005 for Cook Book of the Year Rick Stein's French Odyssey (ISBN 0-56352-213-5), 2005 Rick Stein's Mediterranean Escapes (ISBN 0-563-49366-6), 2007 Rick Stein Coast to Coast (ISBN 9781846076145), 2008 Rick Stein's Far Eastern Odyssey (ISBN 1-84607-716-8), 2009 My Kitchen Table: Rick Stein's 100 Fish and Seafood Recipes (ISBN 9781849901581), 2011 Rick Stein's Spain (ISBN 9781849901352), 2011 Rick Stein's India (ISBN 978-1849905787), 2013 Under a Mackerel Sky: A Memoir (ISBN 0-09194-991-2), 2013 Rick Stein's Long Weekends (ISBN 978-1785940927), 2016 Rick Stein: The Road to Mexico (ISBN 978-1785942006), 2017 Rick Stein's Secret France (ISBN 978-1785943881), 2019 Rick Stein at Home (ISBN 978-1785947087), 2021 Rick Stein's Simple Suppers (ISBN 978-1785948145), 2023 Rick Stein’s Food Stories (ISBN 978-1785948602), 2024 Rick Stein’s Christmas Book (ISBN 978-1785949401), 2025 Rick Stein's Cookery Course (ISBN 978-1785949913), 2026
Sources: en.wikipedia.org
== Function == The protein encoded by this gene is a member of the homeodomain family of DNA binding proteins. It regulates gene expression, morphogenesis, and differentiation and it also plays a role in cell cycle progression, particularly at S-phase. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been determined, and the p200 isoform of Cux1 is processed proteolytically to smaller active isoforms, such as p110. Cux1 DNA binding is stimulated by activation of the PAR2/F2RL1 cell-surface G-protein-coupled receptor in fibroblasts and breast-cancer epithelial cells to regulate Matrix metalloproteinase 10, Interleukin1-alpha, and Cyclo-oxygenase 2 (COX2) genes. Multiple reviews have detailed the tissue-specific functions and genetic interactions in Drosophila and the early characterization of the CDP in mammalian cells, expression and activity of CUX1 in the myeloid cell lineage, multiple CUX1 isoforms, modes of DNA binding, early mouse models and cell-based assays, roles of CUX1 in kidney development and homeostasis, mechanisms by which CUX1 stimulates cell migration and invasion, roles of CUX1 and CUX2 in neurons of the cortex upper layer and the paradoxical implications of CUX1 in cancer. In addition, a number of commentaries present more specific views and speculations.
=== Complications === Problems with bones and joints, including osteoarthritis, nerve compression syndrome due to bony overgrowth, and carpal tunnel syndrome Hypertension Diabetes mellitus Cardiomyopathy, potentially leading to heart failure Colorectal cancer Sleep apnea Thyroid nodules and thyroid cancer Hypogonadism Compression of the optic chiasm by the growth of pituitary adenoma leading to visual problems
Campbell-Bannerman tried to keep these forces together at the head of a moderate Liberal rump, but in 1901 he delivered a speech on the government's "methods of barbarism" in South Africa that pulled him further to the left and nearly tore the party in two. The party was saved after Salisbury's retirement in 1902 when his successor, Arthur Balfour, pushed a series of unpopular initiatives such as the Education Act 1902 and Joseph Chamberlain called for a new system of protectionist tariffs. Campbell-Bannerman was able to rally the party around the traditional liberal platform of free trade and land reform and led them to the greatest election victory in their history. This would prove the last time the Liberals won a majority in their own right. Although he presided over a large majority, Sir Henry Campbell-Bannerman was overshadowed by his ministers, most notably H. H. Asquith at the Exchequer, Edward Grey at the Foreign Office, Richard Burdon Haldane at the War Office and David Lloyd George at the Board of Trade. Campbell-Bannerman retired in 1908 and died soon after. He was succeeded by Asquith, who stepped up the government's radicalism. Lloyd George succeeded Asquith at the Exchequer and was in turn succeeded at the Board of Trade by Winston Churchill, a recent defector from the Conservatives.
Sources: en.wikipedia.org
In Table 5, the approximately $85 billion fine chemical market is subdivided into major applications according to their relevance: fine chemicals for pharmaceuticals, agrochemicals, and specialty chemicals outside life sciences. Furthermore, a distinction is made between captive (in-house) production and merchant market. Pharmaceutical fine chemicals (PFCs) account for two-thirds of the total. Out of the PFC value of $55 billion, about $23 billion (~40%) are traded, and $32 billion (~60%) are the production value of the pharma industry's in-house production. Within life science products, fine chemicals for agro and veterinary drugs follow in importance. The production value for fine chemicals used for specialty chemicals other than pharmaceuticals and agrochemicals is estimated at $15 billion. As the leading specialty chemical companies (Akzo Nobel, Dow, DuPont, Evonik, Chemtura and Mitsubishi) are backward-integrated, the share of in-house production is estimated at 75%, leaving a merchant market of approximately $5 billion.
== Biomedical use == Its bell collagen is currently being researched for use as an intercellular matrix. The collagen is made up of 1/3 glycine and most of the rest is water and other amino acids, its amino acid content is very small. The collagen is denatured as soon as it reaches 29.9 °C (85.8 °F).
==== Breast cancer ==== The comparison of forward and backward SHG images gives insight about the microstructure of collagen, itself related to the grade and stage of a tumor, and its progression in breast. Comparison of SHG and 2PEF can also show the change of collagen orientation in tumors. Even if SHG microscopy has contributed a lot to breast cancer research, it is not yet established as a reliable technique in hospitals, or for diagnostic of this pathology in general.
=== Nucleic acids === The convention for a nucleic acid sequence is to list the nucleotides as they occur from the 5' end to the 3' end of the polymer chain, where 5' and 3' refer to the numbering of carbons around the ribose ring which participate in forming the phosphate diester linkages of the chain. Such a sequence is called the primary structure of the biopolymer.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.